Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions

Last updated:
2026-09-12
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 2 MULTI-CENTER, RANDOMIZED, OPEN-LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF AHB-137 IN NUCLEOS(T)IDE ANALOGUE-TREATED PARTICIPANTS WITH CHRONIC HEPATITIS B IN THE NORTH AMERICA AND EUROPE REGIONS

Intervention/treatment:
AHB-137
Medical condition:
CHRONIC HEPATITIS B
Protocol code:
AB-10-8012
Control number:
503385
Status:
Recruiting
Approved:
July 22, 2026
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT07654283
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 65 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Maggie Davis
Role
CONTACT
Phone:
(650) 650-2877
Sponsor
AUSPERBIO THERAPEUTICS INC.

Locations

Alberta

University of Calgary
Calgary, Alberta, T2N 4N1
NOT_YET_RECRUITING

Ontario

Toronto General Hospital
Toronto, Ontario, M5G 2C4
NOT_YET_RECRUITING
Did you find what you were looking for?